AMPULLA OF VATER STAGING FORM

CLINICAL Extent of disease before any treatment	STAGE CATEGORY D	DEFINITIONS	PATHOLOGIC Extent of disease during and from surgery	
y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	Tumor Size:		y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery	
□ TX □ T0 □ Tis □ T1 □ T2 □ T3 □ T4	TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ T1 Tumor limited to ampulla of Vater or sphi T2 Tumor invades duodenal wall T3 Tumor invades pancreas T4 Tumor invades peripancreatic soft tissues structures other than pancreas	ncter of Oddi	□ TX □ T0 □ Tis □ T1 □ T2 □ T3 □ T4	
□ NX □ N0 □ N1	REGIONAL LYMPH N Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis	IODES (N)	□ NX □ N0 □ N1	
□ M0 □ M1	DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis		□ M1	
Anatomic Stage • Prognostic Groups				
□ 0 Tis □ IA T1 □ IB T2 □ IIA T3 □ IIB T1	CLINICAL N M NO MO NO MO NO MO N1 MO N1 MO N1 MO Any N MO Any N M1	GROUP T N 0 Tis N0 1A T1 N0 1B T2 N0 1IA T3 N0 1IB T1 N1 T2 N1 T3 N1 T4 Any N 1V Any T Any N	M M0 M1	
REQUIRED FOR STAGING: None CLINICALLY SIGNIFICANT: Preoperative or pre-treatment carcinoembryonic antigen (CEA): Preoperative or pre-treatment CA 19-9 lab value: m suffix indicates the presence of multiple primary tumors in a single			For identification of special cases of FNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. In suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses:	
HOSPITAL NAME/ADDRE	ss	PATIENT NAME/INFORMATION		

(continued on next page)

AMPULLA OF VATER STAGING FORM

Histologic Grade (G) (also known as overall grade)		General Notes (continued):		
Grading system □ 2 grade system □ 3 grade system □ 4 grade system □ No 2, 3, or 4 grade system is available □ Grade III or 2 □ No 2, 3, or 4 grade system is available □ Grade IV or 4 Additional Descriptors Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been conversed invasion (LVI) for collection by cancer registrars. The College of America should be used as the primary source. Other sources may be used in the given to positive results.	y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy. r prefix indicates a recurrent tumor when staged after a disease-free			
□ Lymph-Vascular Invasion Not Present (absent)/Not Identified □ Lymph-Vascular Invasion Present/Identified □ Not Applicable □ Unknown/Indeterminate **Residual Tumor (R)** The absence or presence of residual tumor after treatment. In some case neoadjuvant therapy there will be residual tumor at the primary site after resection or local and regional disease that extends beyond the limit of a □ RX Presence of residual tumor cannot be assessed □ R0 No residual tumor □ R1 Microscopic residual tumor □ R2 Macroscopic residual tumor	treatment because of incomplete	interval, and is identified by the "r" prefix: rTNM. a prefix designates the stage determined at autopsy: aTNM. surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report. neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.		
☐ Clinical stage was used in treatment planning (describe):				
□ National guidelines were used in treatment planning □ NCCN □ Other (describe):				
Physician signature	Dat	re/Time		
HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION			

(continued from previous page)